Owners, management and financials
CVR: 35513280
DKK -538,913
Gross profit
Net result: DKK -539,063
NOVOZYMES A/S (15-19,99%), PN INVESTMENT ApS (33,33-49,99%)
2 more
CVR · view owners
Peter Hviid Nordkild
Board: Ejner Bech Jensen (chair) and 4 members
CVR · view management
Active
Founded 6 October 2013
CVR · view overview
0 employees
CVR · 2018
Owner registered: NOVOZYMES A/S
CVR · 27/08/2015
View the full event history
DEFENSIN THERAPEUTICS ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Peter Hviid Nordkild. The board consists of Ejner Bech Jensen (chair), Matthew Alister Cooper, Peter Hviid Nordkild and Robert Ehehalt. The company's owners include NOVOZYMES A/S, PN INVESTMENT ApS and NEVE INVEST ApS. The company has 0 employees (2018). In 2025, the company reported a gross profit of DKK -538,913 and a net result of DKK -539,063 compared with DKK -130,534 the year before. Equity in the 2025 report amounted to DKK 774,437.
Selskabets formål er at drive forskning og udvikling rettet mod udvikling af medicinske produkter, som kan regulere microbiota og dermed relaterede sygdomme, og andre hermed relaterede aktiviteter.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | - | -539 t. | 974 t. | 774 t. | 0 | |
| 202401/01/2024 – 31/12/2024 | - | -131 t. | 1.4 mio. | 1.3 mio. | - | |
| 202301/01/2023 – 31/12/2023 | - | -425 t. | 1.4 mio. | 1.4 mio. | - | |
| 202201/01/2022 – 31/12/2022 | - | -474 t. | 1.8 mio. | 1.7 mio. | - | |
| 202101/01/2021 – 31/12/2021 | 0 | -366 t. | 2.2 mio. | 2.1 mio. | - | |
| 202001/01/2020 – 31/12/2020 | - | -2.3 mio. | 2.7 mio. | 2.5 mio. | 0 | |
| 201901/01/2019 – 31/12/2019 | - | -1.7 mio. | 5 mio. | 4.8 mio. | 1 | |
| 201801/01/2018 – 31/12/2018 | - | -3 mio. | 1.1 mio. | 1 mio. | - | |
| 201701/01/2017 – 31/12/2017 | 0 | -2 mio. | 4.1 mio. | 3.9 mio. | - | |
| 201601/01/2016 – 31/12/2016 | 11.1 mio. | 6 mio. | 7.7 mio. | 6 mio. | 1 | |
| 201501/01/2015 – 31/12/2015 | - | -811 t. | 242 t. | -53 t. | - |
Compared to 1.039 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorThe CVR number of DEFENSIN THERAPEUTICS ApS is 35513280.
The owners of DEFENSIN THERAPEUTICS ApS include NOVOZYMES A/S, PN INVESTMENT ApS and NEVE INVEST ApS.
The management of DEFENSIN THERAPEUTICS ApS consists of Peter Hviid Nordkild.
The board of DEFENSIN THERAPEUTICS ApS consists of Ejner Bech Jensen, Matthew Alister Cooper and Peter Hviid Nordkild, with Ejner Bech Jensen as chair.
In 2025, DEFENSIN THERAPEUTICS ApS reported a gross profit of DKK -538,913.
DEFENSIN THERAPEUTICS ApS had 0 employees in 2018 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
DEFENSIN THERAPEUTICS ApS has published its annual report for 2025. Gross profit came to DKK -538,913, and the net result was DKK -539,063.
Contact info changed: new phone: 25471646, new email: [email protected], new website: www.defensintherapeutics.com (May 27, 2026).
Contact info changed: new phone: 25471646, new email: [email protected], new website: www.defensintherapeutics.com (February 26, 2026).
DEFENSIN THERAPEUTICS ApS has published its annual report for 2024. The net result was DKK -130,534.
As of June 19, 2025, EY Godkendt Revisionspartnerselskab has stepped down as auditor of DEFENSIN THERAPEUTICS ApS.
DEFENSIN THERAPEUTICS ApS has published its annual report for 2023. The net result was DKK -425,344.
DEFENSIN THERAPEUTICS ApS has published its annual report for 2022. The net result was DKK -473,890.
DEFENSIN THERAPEUTICS ApS has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -365,611.
DEFENSIN THERAPEUTICS ApS has published its annual report for 2020. The net result was DKK -2,315,678.
DEFENSIN THERAPEUTICS ApS has published its annual report for 2019. The net result was DKK -1,721,113.
DEFENSIN THERAPEUTICS ApS has published its annual report for 2018. The net result was DKK -2,952,934.
As of April 30, 2019, Robert Ehehalt has joined the board of directors of DEFENSIN THERAPEUTICS ApS.
As of April 30, 2019, Jan Wehkamp has left the board of directors of DEFENSIN THERAPEUTICS ApS.
DEFENSIN THERAPEUTICS ApS has published its annual report for 2017. Revenue came to DKK 0, and the net result was DKK -2,032,581.
DEFENSIN THERAPEUTICS ApS has published its annual report for 2016. Revenue came to DKK 11,142,900, and the net result was DKK 6,028,313.
DEFENSIN THERAPEUTICS ApS has published its annual report for 2015. The net result was DKK -811,429.
As of December 10, 2015, Peter Hviid Nordkild has joined the board of directors of DEFENSIN THERAPEUTICS ApS.
As of December 10, 2015, Ejner Bech Jensen has joined the board of directors of DEFENSIN THERAPEUTICS ApS.
As of December 10, 2015, Søren Neve has joined the board of directors of DEFENSIN THERAPEUTICS ApS.
As of December 10, 2015, Matthew Alister Cooper has joined the board of directors of DEFENSIN THERAPEUTICS ApS.
As of December 10, 2015, Jan Wehkamp has joined the board of directors of DEFENSIN THERAPEUTICS ApS.
As of August 27, 2015, NOVOZYMES A/S is registered as an owner of DEFENSIN THERAPEUTICS ApS with an ownership share of 15%.
As of August 27, 2015, PN INVESTMENT ApS is registered as an owner of DEFENSIN THERAPEUTICS ApS with an ownership share of 33%.
As of August 27, 2015, NEVE INVEST ApS is registered as an owner of DEFENSIN THERAPEUTICS ApS with an ownership share of 15%.
As of August 27, 2015, is registered as an owner of DEFENSIN THERAPEUTICS ApS with an ownership share of 15%.
DEFENSIN THERAPEUTICS ApS has published its interim report for the period October 6, 2013 – December 31, 2014.
As of April 17, 2015, JUT NR. 2180 A/S has been appointed auditor of DEFENSIN THERAPEUTICS ApS.
As of April 17, 2015, EY Godkendt Revisionspartnerselskab has been appointed auditor of DEFENSIN THERAPEUTICS ApS.
As of April 17, 2015, JUT NR. 2180 A/S has stepped down as auditor of DEFENSIN THERAPEUTICS ApS.
As of October 6, 2013, Peter Hviid Nordkild is registered as adm. dir. of DEFENSIN THERAPEUTICS ApS.
DEFENSIN THERAPEUTICS ApS was founded on October 6, 2013.
Companies in the same industry and area
CVR 29418888
CVR 29769796
CVR 34688605
CVR 34892970
CVR 35047565
